Healthcare
Tsumura & Co.(TSMRF)
Live Price
Offline$23.20
+0.00% today
1Y Change
-17.58%
Window
Jun 20, 2025 → Jun 12, 2026
- Market Cap
- $270.60B
- Revenue Growth
- +20.1%
- EPS Growth
- +94.3%
- Dividend Yield
- 4.0%
Coverage: 252 bars · Jun 20, 2025 → Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Tsumura & Co. (TSMRF) is a Healthcare stock with a market cap of $270.60B and listed on OTC. The stock last traded around $23.20 and down 17.6% across the available one-year price window (Jun 20, 2025 → Jun 12, 2026). Baseline metrics include revenue growth of +20.1%, EPS growth of +94.3%, a dividend yield of 4.0%. What stands out right now is revenue +20.1%, EPS +94.3%, free cash flow +127.9% with operating margin 19.3% and ROIC 5.6%. The dividend matters to the case here, with a current yield around 4.0%. Valuation is more restrained than many high-expectation growth names at P/E 9.3 and price/sales 1.4. Overall, the current profile looks closer to a income-oriented value setup than a generic broad-market placeholder. Stock Foundry combines TSMRF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+20.1% vs +7.6% peer median
Operating Margin
Near sector median
+19.3% vs +19.4% peer median
P/E
Below sector median
9.3 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
The operating story is still moving forward
Revenue is running at +20.1% and EPS at +94.3%, with operating margin around 19.3%.
Shareholder return is still part of the story
The stock is still offering a dividend yield around 4.0%, which matters if the thesis depends on income as much as growth.
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
TSMRF
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
TSMRF Max Drawdown
-17.58%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for TSMRF and SPY.
Company Overview
Tsumura & Co.
Other OTC
Tsumura & Co. engages in the manufacture and sale of pharmaceutical products worldwide. The company offers Kampo extract intermediates and granular Kampo formulations. It is involved in the procurement, selection and processing, and storage of raw material crude drugs and crude drug pieces for decoction; manufacture of Kampo powdered extracts and traditional Chinese medicines; and sale of pharmaceuticals and food products. The company was founded in 1893 and is headquartered in Tokyo, Japan.
- Leadership
- Terukazu Kato
- IPO Date
- Feb 22, 2013
- Employees
- 4.1k
- Street Address
- 2-17-11, Akasaka
- Mailing
- Tokyo, 107-8521
- Region
- Tokyo, JP
- Reporting Currency
- USD
- Investor Line
- 81 3 6361 7101
- Last Updated
- May 5, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 9.3
- EV/EBITDA
- 6.3
- Price/Sales
- 1.4
- Price/Book
- 0.9
Growth
- Revenue
- +20.1%
- EPS
- +94.3%
- Free Cash Flow
- +127.9%
Profitability
- Gross Margin
- 47.6%
- Operating Margin
- 19.3%
- Net Margin
- 15.3%
- ROE
- 9.8%
- ROIC
- 5.6%
Balance Sheet
- Debt/Equity
- 0.44
- Current Ratio
- 2.65
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.